In a patient with myasthenia gravis presenting with dysphonia (loss of voice), what does this indicate and how should it be managed?

Loss of Voice in Myasthenia Gravis

In a patient with myasthenia gravis presenting with dysphonia, this indicates laryngeal muscle involvement (bulbar weakness) and requires immediate laryngoscopy to visualize the vocal folds, followed by treatment with acetylcholinesterase inhibitors (pyridostigmine) as first-line therapy, with immunosuppressive therapy added for inadequate response.

Clinical Significance

Dysphonia as a manifestation of MG represents involvement of the laryngeal muscles due to neuromuscular junction dysfunction. While rare as an isolated or primary presentation, laryngeal MG can occur and may persist for years without other muscle group involvement 1, 2. This presentation is frequently misdiagnosed, with patients often initially suspected of having stroke or other neurological conditions 3.

Diagnostic Approach

Immediate Evaluation Required

Perform laryngoscopy urgently - do not delay visualization of the larynx 4. The general dysphonia guidelines recommend laryngoscopy within 4 weeks for persistent dysphonia, but in a known MG patient, this should be expedited to:

• Document vocal fold paresis or paralysis (typically bilateral and diffuse) 1
• Rule out other serious causes of dysphonia
• Establish baseline laryngeal function

Confirmatory Testing

Voice spectrography before and after edrophonium (Tensilon) test provides objective documentation of improvement and confirms the myasthenic etiology 5. This is particularly valuable when:

• Anti-acetylcholine receptor (AChR) antibodies are negative (common in laryngeal MG - only 1/7 patients seropositive in one series) 2
• Anti-MuSK antibodies are absent 2
• Repetitive nerve stimulation is normal 1

Single-fiber electromyography (SFEMG) of laryngeal muscles should be performed when other tests are negative but clinical suspicion remains high 6, 1. This is the most sensitive test for laryngeal MG and may be the only abnormal finding.

Important Caveat

Do NOT obtain CT or MRI prior to laryngoscopy 4. This is a common pitfall - imaging should follow, not precede, direct visualization of the larynx.

Management Algorithm

First-Line Treatment

Initiate pyridostigmine (acetylcholinesterase inhibitor) immediately upon diagnosis 7, 2:

• Standard dosing: 60 mg orally, titrated to symptom control
• Expect significant improvement in voice quality 3, 5, 1
• May be sufficient for mild laryngeal involvement alone

Escalation for Inadequate Response

Add corticosteroids when symptoms persist despite cholinesterase inhibitors 7, 8, 9:

• Corticosteroids are the mainstay of immunosuppressive treatment for more than mild MG
• Essential for inducing remission or achieving minimal manifestations

Consider steroid-sparing immunosuppressants (azathioprine) when:

• Comorbidities preclude or restrict steroid use
• Long-term immunosuppression is needed 7

Refractory Cases

For patients not responding to conventional therapy 7, 8:

• Rituximab for refractory MG
• Plasmapheresis or IVIG for acute exacerbations or crisis
• Novel biologics: Complement inhibitors or neonatal Fc receptor antagonists (recently approved with excellent efficacy/safety profiles) 8

Thymectomy Consideration

Evaluate for thymoma with chest imaging after laryngoscopy 2:

• Extended thymectomy indicated for thymus hyperplasia or thymic tumor
• For generalized AChR antibody-positive MG, thymectomy is beneficial up to age 65, ideally within 2 years of onset 7, 9

Critical Pitfalls to Avoid

1. Misdiagnosis as stroke/TIA - The fluctuating nature and isolated dysphonia can mimic transient ischemic attacks 3. Look for fatigability pattern and lack of other stroke features.

2. Assuming seronegative = not MG - Laryngeal MG has surprisingly low seropositivity rates for both AChR and MuSK antibodies 1, 2. Proceed with SFEMG and therapeutic trial even when antibodies are negative.

3. Delaying laryngoscopy - Direct visualization is mandatory and should not be delayed for imaging or other testing 4.

4. Prescribing empiric reflux medications - Do not treat isolated dysphonia with antireflux therapy without laryngoscopy 4. This delays correct diagnosis.

5. Assuming generalization will occur - While most laryngeal MG eventually involves other muscles, isolated laryngeal involvement can persist for decades (documented up to 26 years) 1.

Monitoring and Follow-up

Document voice outcomes systematically using:

• Voice Handicap Index (76% of MG patients experience at least mild handicap) 10
• Acoustic analysis parameters (jitter, shimmer, noise-to-harmonic ratio) 10
• MG-specific scales (MG-ADL, QMG score) 9

Long-term surveillance is essential as isolated laryngeal MG can remain localized for years but requires ongoing monitoring for potential generalization 1, 2.